A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

NCT05815680 · Completed

Last updated 2026-05-28

This study tests how the diabetes medication IBI362 interacts with common drugs like metformin, warfarin, atorvastatin, and digoxin in adults who are overweight or obese.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 48 people

Who can join Ages 18–45 · male only Healthy volunteers accepted.

Timeline Started 2023-04 · est. completion 2023-10

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05815680 ↗

Description as written by the study sponsor.

This trial is conducted in China. The aim of the trial is to investigate the influence of IBI362 on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of warfarin, metformin, warfarin, atorvastatin, digoxin in overweight or obese subjects.

Treatments tested

metformin Drug

For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
digoxin Drug

For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
IBI362 Drug

Subjects will initiate treatment with 2 mg for the first four weeks followed by 4mg for four weeks and up to a dose of 6 mg for six weeks.
warfarin Drug

For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
atorvastatin Drug

For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.

Main thing measured	Maximum observed metformin plasma concentration at steady state
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions studied	Overweight Subjects, Obese Subjects
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05815680 ↗